Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Lehtonen, H. Karvonen, E. Lappi-Blanco, R. Sormunen, U. Zagai, M. Sköld, R. Kaarteenaho (Oulu, Finland; Stockhom, Sweden). Pirfenidone and BIBF1120 regulate properties of myofibroblasts. Eur Respir J 2014; 44: Suppl. 58, 3502

Member's Comments

No comment yet.

Related content which might interest you: Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Pirfenidone therapy for patients with progressive idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Sensitivity analyses from the INPULSIS™ trials of nintedanib Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Parenchymal cell populations involved in the development of fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Idiopathic pulmonary fibrosis is associated with a preferential alteration of kCO rather than of DLCO Source: International Congress 2014 – ILDs 6 Year: 2014 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 LATE-BREAKING ABSTRACT: The effects and mechanism of adiponectin on inhibiting pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014